<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917757</url>
  </required_header>
  <id_info>
    <org_study_id>NAPACA-Outcome</org_study_id>
    <nct_id>NCT04917757</nct_id>
  </id_info>
  <brief_title>Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas</brief_title>
  <acronym>NAPACA</acronym>
  <official_title>Clinical Outcome of Autonomous Cortisol Secretion in Adrenal Incidentalomas - Substudy of the ENSAT (European Network for the Study of Adrenal Tumor) Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Network for the Study of Adrenal Tumors</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to assess mortality and cardiovascular events potentially&#xD;
      linked to cortisol excess in patients with adrenal incidentalomas stratified by cortisol&#xD;
      values following the 1-mg overnight dexamethasone test.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The NAPACA Outcome Study is part of the ENSAT Registry (https://registry.ensat.org/)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">May 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018</time_frame>
    <description>death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular morbidity</measure>
    <time_frame>From date of primary diagnosis of the adrenal incidentaloma until December 31, 2018</time_frame>
    <description>Cardiovascular (CV) events (myocardial infarction, percutaneous coronary intervention, coronary bypass, stroke, deep vein thrombosis, and pulmonary embolism)</description>
  </secondary_outcome>
  <enrollment type="Actual">4374</enrollment>
  <condition>Adrenal Incidentaloma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>1mg Dexamethasone test</intervention_name>
    <description>For each patient a 1mg dexamethasone test has been performed.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with adrenal incidentaloma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥18 years&#xD;
&#xD;
          -  adrenal incidentaloma (≥ 1cm) detected by cross-sectional imaging between January 1,&#xD;
             1996 and December 31, 2015&#xD;
&#xD;
          -  imaging characteristics suggestive for an adrenal adenoma or excluded malignancy by&#xD;
             follow-up imaging&#xD;
&#xD;
          -  availability of a 1 mg dexamethasone test result&#xD;
&#xD;
          -  follow-up data on living status and occurrence of cardiovascular events&#xD;
&#xD;
          -  follow-up duration of at least 36 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  proven pheochromocytoma, primary hyperaldosteronism or adrenocorticotropic hormone&#xD;
             (ACTH)-dependent Cushing's syndrome&#xD;
&#xD;
          -  clinical features suggestive for overt Cushing's syndrome; urinary free cortisol (UFC)&#xD;
             ≥ 2-fold higher than the upper limit of normal of the local assay&#xD;
&#xD;
          -  any active malignancy (including adrenocortical cancer) at the time of primary&#xD;
             diagnosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Fassnacht, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Turin</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuerzburg University Hospital</investigator_affiliation>
    <investigator_full_name>Martin Fassnacht</investigator_full_name>
    <investigator_title>Chair Dept. of Endocrinology and Diabetes</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocortical Adenoma</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>not yet decided.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

